Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian I Rini

Showing results (11-20 of 401) with videos related to

Pageof 41
Sort By:
Expert Review of Anticancer Therapy|December 22, 2006
Molecularly targeted therapy in renal cell carcinoma: where do we go from here?Brian I Rini
Nature Clinical Practice. Oncology|November 3, 2005
What are the prognostic factors for survival in patients with metastatic renal cell carcinoma?Brian I Rini
Clinical Advances in Hematology & Oncology : H&O|October 18, 2012
Highlights in renal cell carcinoma from the 2012 American Society of Clinical Oncology Annual MeetingBrian I Rini
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2018
Goldilocks Dosing of TKIs: A Dose that Is Just Right Leads to Optimal OutcomesBrian I Rini
Clinical Advances in Hematology & Oncology : H&O|May 10, 2018
Current and emerging first-line systemic therapies in clear cell renal cell carcinomaBrian I Rini
Nature Clinical Practice. Oncology|September 3, 2008
Lapatinib therapy for patients with advanced renal cell carcinomaBrian I Rini
Cancer|April 30, 2009
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinomaBrian I Rini
Clinical Advances in Hematology & Oncology : H&O|November 11, 2008
Update on the use of mTOR inhibitors in renal cell carcinomaBrian I Rini
The Lancet. Oncology|October 22, 2011
Targeted therapy for patients with renal-cell carcinomaBrian I Rini
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2013
The context of blood vessels and response to VEGF-targeted therapyBrian I Rini
Pageof 41

Showing results (11-20 of 401) with videos related to

Sort By:
Pageof 41
Expert Review of Anticancer Therapy|December 22, 2006
Molecularly targeted therapy in renal cell carcinoma: where do we go from here?Brian I Rini
Nature Clinical Practice. Oncology|November 3, 2005
What are the prognostic factors for survival in patients with metastatic renal cell carcinoma?Brian I Rini
Clinical Advances in Hematology & Oncology : H&O|October 18, 2012
Highlights in renal cell carcinoma from the 2012 American Society of Clinical Oncology Annual MeetingBrian I Rini
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2018
Goldilocks Dosing of TKIs: A Dose that Is Just Right Leads to Optimal OutcomesBrian I Rini
Clinical Advances in Hematology & Oncology : H&O|May 10, 2018
Current and emerging first-line systemic therapies in clear cell renal cell carcinomaBrian I Rini
Nature Clinical Practice. Oncology|September 3, 2008
Lapatinib therapy for patients with advanced renal cell carcinomaBrian I Rini
Cancer|April 30, 2009
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinomaBrian I Rini
Clinical Advances in Hematology & Oncology : H&O|November 11, 2008
Update on the use of mTOR inhibitors in renal cell carcinomaBrian I Rini
The Lancet. Oncology|October 22, 2011
Targeted therapy for patients with renal-cell carcinomaBrian I Rini
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2013
The context of blood vessels and response to VEGF-targeted therapyBrian I Rini
Pageof 41